Literature DB >> 10640545

Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies.

A Ibáñez1, B Clotet, M A Martínez.   

Abstract

The impact of emergence of genetic resistance, soon after the beginning of antiretroviral therapy, on the genotype of other viral loci not implicated in the development of resistance was studied in four human immunodeficiency type 1 (HIV-1)-infected patients subjected to indinavir monotherapy. Two patients were chosen because they showed no decrease in virus load during the study period and two were selected because they showed a rapid decline in plasma viraemia after the initiation of therapy and a virus rebound after 12 weeks of treatment. The evolution of virus sequences was analysed within the four infected patients by examining virus sequences spanning the protease and C2-V3 env genes by RT-PCR of plasma samples obtained at the beginning and after 12 weeks of therapy. PCR products from the two genomic regions from the two sample points per patient were cloned and 10-15 clones from each sample were sequenced. Genotypic indinavir resistance was present in the four patients after 12 weeks of therapy. The overall protease and C2-V3 env regions quasispecies diversity at time zero was higher than that after 12 weeks of therapy, but this difference was more significant in the two patients who showed a reduction in virus load soon after the initiation of treatment. C2-V3 env sequences indicated that changes during emergence of resistance to indinavir were only detected in the two patients who showed a drastic reduction in virus load. Thus, a temporal relationship was observed between the start of therapy, a drastic reduction in virus load and a drift in the HIV-1 env quasispecies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640545     DOI: 10.1099/0022-1317-81-1-85

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  Genetic bottlenecks reduce population variation in an experimental RNA virus population.

Authors:  Hongye Li; Marilyn J Roossinck
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

2.  Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.

Authors:  Magdalena Magierowska; Flavien Bernardin; Seema Garg; Silvija Staprans; Michael D Miller; Koen K A Van Rompay; Eric L Delwart
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Analysis of selection pressure and mutational pattern of HIV type 1 reverse transcriptase region among treated and nontreated patients.

Authors:  Uma Shanmugasundaram; Suniti Solomon; Vidya Madhavan; Murugavel G Kailapuri; Kumarasamy Nagalingeswaran; Sunil Suhas Solomon; Kenneth H Mayer; Balakrishnan Pachamuthu
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-19       Impact factor: 2.205

4.  Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression.

Authors:  Ryan M Troyer; Kalonji R Collins; Awet Abraha; Erika Fraundorf; Dawn M Moore; Randall W Krizan; Zahra Toossi; Robert L Colebunders; Mark A Jensen; James I Mullins; Guido Vanham; Eric J Arts
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Population genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay.

Authors:  L Doukhan; E Delwart
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations.

Authors:  Kathryn M Kitrinos; Julie A E Nelson; Wolfgang Resch; Ronald Swanstrom
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Co-lethality studied as an asset against viral drug escape: the HIV protease case.

Authors:  Sophie Brouillet; Thomas Valere; Emmanuelle Ollivier; Laurent Marsan; Anne Vanet
Journal:  Biol Direct       Date:  2010-06-17       Impact factor: 4.540

8.  Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment.

Authors:  Tamara Nora; Charlotte Charpentier; Olivier Tenaillon; Claire Hoede; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

9.  Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.

Authors:  Shigeyoshi Harada; Kazuhisa Yoshimura; Aki Yamaguchi; Samatchaya Boonchawalit; Keisuke Yusa; Shuzo Matsushita
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

10.  Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation.

Authors:  Matthew J Gonzales; Eric Delwart; Soo-Yon Rhee; Rose Tsui; Andrew R Zolopa; Jonathan Taylor; Robert W Shafer
Journal:  J Infect Dis       Date:  2003-07-10       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.